Abstract 4700: A novel selective EZH2 inhibitor exhibits anti-tumor activity in lymphoma with EZH2 activating mutations
Caretha L. Creasy, Peter J. Tummino(Intarcia Therapeutics (United States)), Charles F. McHugh(GlaxoSmithKline (United States)), Michael T. McCabe(GlaxoSmithKline (United States)), Louis V. LaFrance(Johnson & Johnson (United States)), Sharad K. Verma(GlaxoSmithKline (United States)), Elsie Diaz(Johnson & Johnson (United States)), Gopi Ganji(GlaxoSmithKline (United States)), Heidi M. Ott(GlaxoSmithKline (United Kingdom)), Shelby Gorman(GlaxoSmithKline (United States)), Susan Korenchuk(GlaxoSmithKline (United Kingdom)), Christine S. Thompson(Molecular Oncology (United States)), Martín Brandt(SINTEF)
Cited by 3
Related Papers
Genomic-sequence comparison of two unrelated isolates of the human gastric pathogen Helicobacter pylori
|Nature|1999|1.9k
EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
|Nature|2012|1.8k
Hydrolysis of Biological Peptides by Human Angiotensin-converting Enzyme-related Carboxypeptidase
|Journal of Biological Chemistry|2002|1.4k
Residence Time of Receptor−Ligand Complexes and Its Effect on Biological Function
|Biochemistry|2008|550